Sopharma Trading : introduces to the Bulgarian market a patented technology for automatic injection of CO2 gas in vascular procedures in partnership with Angiodroid Srl

As a company that drives the evolution in healthcare, today we announce our new partnership with Angiodroid Srl, a unique manufacturer of specialized automatic carbon dioxide (CO₂) injector systems. Together we will introduce the Angiodroid system to the Bulgarian market, providing a patented technology for automatic injection of CO₂ gas during vascular procedures.

This technological solution is a decisive factor for patients with contraindications and severe intolerance to iodine agents, but it is also fully applicable in milder clinical cases. The injection of CO₂ gas is completely harmless to the body аnd it is absorbed by the vascular system seconds after each intervention. The clinical images provides high contrast quality comparable to the quality of images obtained by using an iodine contrast.

"We are extremely proud to partner with Angiodroid Srl and to provide to the Bulgarian market a unique solution for CO₂ vascular procedures. Our mission is to offer equipment to medical specialists, that improves and facilitates their work, but also give security and create peace of mind for patients. Angiodroid integrates new technologies to ensure the highest level of injection precision without human intervention. The system enables medical facilities to significantly reduce the severe allergic reactions as a result of iodinated contrast agents' usage, to improve its healthcare services, to ensure patients safety, and to optimize the costs ", said Michaela Karamanolova, Medical Equipment Solutions Director in Sopharma Trading.